Trial Profile
A Single-Center, Placebo-Controlled, Rising Dose to Tolerance and Safety Study of TD101, an siRNA Designed for Treatment of Pachyonychia Congenita
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs TD 101 (Primary)
- Indications Pachyonychia congenita
- Focus Adverse reactions
- 25 Apr 2016 New trial record